grade
pharmaceutical primary standard
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−70°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Packaging
Unit quantity: 0.3 mL. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
PLEASE NOTE: TEMPORARILY UNAVAILABLE DUE TO RESTRICTED QUANTITY
Storage Class
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Hejna et al.
European journal of cancer (Oxford, England : 1990), 37(16), 1994-2002 (2001-10-13)
We have conducted a prospective controlled randomised clinical study testing for the efficacy of topical GM-CSF (molgramostim), as compared to the combined topical use of an antiseptic agent (povidone-iodine) and amphotericin B (AA) in patients with chemotherapy-induced mucositis World Health
Xavier Thomas
Expert opinion on drug metabolism & toxicology, 4(6), 795-806 (2008-07-10)
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates the proliferation and differentiation of hematopoietic progenitor cells in the myeloid lineage, and plays a key role in host defence and the inflammatory process. The main schedules adopted for clinical applications of GM-CSF in
G M Sprinzl et al.
European journal of cancer (Oxford, England : 1990), 37(16), 2003-2009 (2001-10-13)
The combination of radiation and chemotherapy administered for patients undergoing therapy for advanced head and neck neoplasms leads to a significant rise in toxic side-effects. Oral mucositis remains one of the most distressing factors leading to pain, impairment of oral
Mehmet A Gulcelik et al.
Canadian journal of surgery. Journal canadien de chirurgie, 48(3), 213-218 (2005-07-15)
Several systemic factors, including jaundice, long-term corticosteroid therapy, diabetes and malnutrition, increase the risk of anastomotic dehiscence. The local application of molgramostim (recombinant human granulocyte-macrophage colony stimulating factor) has been reported to improve impaired dermal wound healing. Since jaundice, one
Pavlos M Myrianthefs et al.
Scandinavian journal of infectious diseases, 35(3), 175-179 (2003-05-20)
The aim of this uncontrolled, prospective, clinical study was to investigate the efficacy and safety of molgramostim administration in patients with severe sepsis. The subjects were 20 critically ill, mechanically ventilated patients with severe sepsis in a university intensive care
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service